Impact of direct acting antiviral (DAA) treatment on glucose metabolism and reduction of pre-diabetes in patients with chronic hepatitis C

• Verfasst von: Weidner, Philip [VerfasserIn]
• Verfasst von: Böttche, Dominik [VerfasserIn]
• Verfasst von: Burgermeister, Elke [VerfasserIn]
• Verfasst von: Teufel, Andreas [VerfasserIn]
• Verfasst von: Ebert, Matthias [VerfasserIn]
• Verfasst von: Antoni, Christoph Helmer [VerfasserIn]
• Titel: Impact of direct acting antiviral (DAA) treatment on glucose metabolism and reduction of pre-diabetes in patients with chronic hepatitis C
• Verf.angabe: Philip Weidner, Dominik Boettche, Thomas Zimmerer, Elke Burgermeister, Andreas Teufel, Matthias P.A. Ebert, Christoph Antoni
• Jahr: 2018
• Umfang: 9 S.
• Fussnoten: Gesehen am 03.07.2019
• Titel Quelle: Enthalten in: Journal of gastrointestinal and liver diseases
• Ort Quelle: Cluj-Napoca : Soc., 2006
• Jahr Quelle: 2018
• Band/Heft Quelle: 27(2018), 3, Seite 281-289
• ISSN Quelle: 1842-1121
• DOI: doi:10.15403/jgld.2014.1121.273.daa
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Antiviral Agents
• Sach-SW: Biomarkers
• Sach-SW: Blood Glucose
• Sach-SW: Drug Therapy, Combination
• Sach-SW: Female
• Sach-SW: Germany
• Sach-SW: Glycated Hemoglobin A
• Sach-SW: Hepatitis C, Chronic
• Sach-SW: Humans
• Sach-SW: Liver
• Sach-SW: Liver Cirrhosis
• Sach-SW: Male
• Sach-SW: Middle Aged
• Sach-SW: Prediabetic State
• Sach-SW: Retrospective Studies
• Sach-SW: Risk Factors
• Sach-SW: Time Factors
• Sach-SW: Treatment Outcome
• K10plus-PPN: 1668436124

Abstract

BACKGROUND AND AIM: With the development of direct acting antiviral agents (DAA) chronic hepatitis C virus (HCV) infection has become curable in most patients. Since HCV infection is known to have direct and/or indirect effects on glucose metabolism, successful HCV treatment may have an impact in reducing glucose level, pre-diabetes, the need of treatment for diabetes, and ultimately diabetes-associated morbidity. We investigated the association of DAA treatment and glucose metabolism in the context of development or resolution of hepatic fibrosis in a large cohort of HCV- infected patients. - METHODS: In this retrospective single-center observational study, we investigated 281 patients receiving all-oral DAA therapy for fasting plasma glucose, HbA1c, liver enzymes and general clinical chemistry, measured during a 52-week follow-up. In addition, elastography, FIB-4- and APRI-calculation were used to assess hepatic fibrosis non-invasively. - RESULTS: Successful elimination of HCV through DAA treatment was associated with a significant drop in fasting glucose level and a reduced rate of impaired fasting plasma glucose (FPG). Interestingly, this metabolic change was BMI-independent. In addition, long-term glucose levels also decreased after successful DAA treatment. A significant APRI-score reduction was associated with a persistent improvement of FPG. However, DAA did not have an impact on glucose metabolism in patients suffering from liver cirrhosis. - CONCLUSION: This study highlights the beneficial impact of successful HCV therapy on glucose metabolism and identifies patients with liver cirrhosis as a collective in need of intensified surveillance with regard to diabetes progression despite HCV eradication.